U.S. PHARMACOPEIA

Search USP29  

V. RATIONALE AND ACTION PLAN FOR VIRAL CLEARANCE STUDIES AND VIRUS TESTS ON PURIFIED BULK
It is important to design the most relevant and rational protocol for virus tests from the MCB level, through the various steps of drug production, to the final product including evaluation and characterization of viral clearance from unprocessed bulk. The evaluation and characterization of viral clearance plays a critical role in this scheme. The goal should be to obtain the best reasonable assurance that the product is free of virus contamination.
In selecting viruses to use for a clearance study, it is useful to distinguish between the need to evaluate processes for their ability to clear viruses that are known to be present and the desire to estimate the robustness of the process by characterizing the clearance of nonspecific “model” viruses (described later). Definitions of “relevant,” specific, and nonspecific “model” viruses are given in the glossary. Process evaluation requires knowledge of how much virus may be present in the process, such as the unprocessed bulk, and how much can be cleared in order to assess product safety. Knowledge of the time dependence for inactivation procedures is helpful in assuring the effectiveness of the inactivation process. When evaluating clearance of known contaminants, in-depth, time-dependent inactivation studies, demonstration of reproducibility of inactivation/removal, and evaluation of process parameters should be provided. When a manufacturing process is characterized for robustness of clearance using nonspecific “model” viruses, particular attention should be paid to nonenveloped viruses in the study design. The extent of viral clearance characterization studies may be influenced by the results of tests on cell lines and unprocessed bulk. These studies should be performed as described in section VI. below.
Table 4 presents an example of an action plan in terms of process evaluation and characterization of viral clearance as well as virus tests on purified bulk, in response to the results of virus tests on cells and/or the unprocessed bulk. Various cases are considered. In all cases, characterization of clearance using nonspecific “model” viruses should be performed. The most common situations are Cases A and B. Production systems contaminated with a virus other than a rodent retrovirus are normally not used. Where there are convincing and well justified reasons for drug production using a cell line from Cases C, D, or E, these should be discussed with the regulatory authorities. With Cases C, D, and E, it is important to have validated effective steps to inactivate/remove the virus in question from the manufacturing process.
Table 4. Action Plan for Process Assessment of Viral Clearance and Virus Tests on Purified Bulk
Case A Case B Case C2 Case D2 Case E2
Status
Presence of virus1 + + (+)3
Virus-like particles1 (+)3
Retrovirus-like particles1 + (+)3
Virus identified not applicable + + +
Virus pathogenic for humans not applicable 4 4 + unknown
Action
Process characterization of viral clearance
using nonspecific “model” viruses
yes5 yes5 yes5 yes5 yes7
Process evaluation of viral clearance using
“relevant” or specific “model” viruses
no yes6 yes6 yes6 yes7
Test for virus in purified bulk not applicable yes8 yes8 yes8 yes8
1  Results of virus tests for the cell substrate and/or at the unprocessed bulk level. Cell cultures used for production which are contaminated with viruses will generally not be acceptable. Endogenous viruses (such as retroviruses) or viruses that are an integral part of the MCB may be acceptable if appropriate viral clearance evaluation procedures are followed.
2  The use of source material which is contaminated with viruses, whether or not they are known to be infectious and/or pathogenic in humans, will only be acceptable under very exceptional circumstances.
3  Virus has been observed by either direct or indirect methods.
4  Believed to be nonpathogenic.
5  Characterization of clearance using nonspecific “model” viruses should be performed.
6  Process evaluation for “relevant” viruses or specific “model” viruses should be performed.
7  See text under Case E.
8  The absence of detectable virus should be confirmed for purified bulk by means of suitable methods having high specificity and sensitivity for the detection of the virus in question. For the purpose of marketing authorization, data from at least 3 lots of purified bulk manufactured at pilot-plant or commercial scale should be provided. However for cell lines such as CHO cells for which the endogenous particles have been extensively characterized and adequate clearance has been demonstrated, it is not usually necessary to assay for the presence of the noninfectious particles in purified bulk.
Case A: Where no virus, virus-like particle, or retrovirus-like particle has been demonstrated in the cells or in the unprocessed bulk, virus removal and inactivation studies should be performed with nonspecific “model” viruses as previously stated.
Case B: Where only a rodent retrovirus (or a retrovirus-like particle that is believed to be nonpathogenic, such as rodent A- and R-type particles) is present, process evaluation using a specific “model” virus, such as a murine leukemia virus, should be performed. Purified bulk should be tested using suitable methods having high specificity and sensitivity for the detection of the virus in question. For marketing authorization, data from at least three lots of purified bulk at pilot-plant scale or commercial scale should be provided. Cell lines such as Chinese hamster ovary (CHO), C127, baby hamster kidney (BHK), and murine hybridoma cell lines have frequently been used as substrates for drug production with no reported safety problems related to viral contamination of the products. For these cell lines in which the endogenous particles have been extensively characterized and clearance has been demonstrated, it is not usually necessary to assay for the presence of the noninfectious particles in purified bulk. Studies with nonspecific “model” viruses, as in Case A, are appropriate.
Case C: When the cells or unprocessed bulk are known to contain a virus, other than a rodent retrovirus, for which there is no evidence of capacity for infecting humans (such as those identified by footnote 2 in Table 3, except rodent retroviruses (Case B)), virus removal and inactivation evaluation studies should use the identified virus. If it is not possible to use the identified virus, “relevant” or specific “model” viruses should be used to demonstrate acceptable clearance. Time-dependent inactivation for identified (or “relevant” or specific “model”) viruses at the critical inactivation step(s) should be obtained as part of process evaluation for these viruses. Purified bulk should be tested using suitable methods having high specificity and sensitivity for the detection of the virus in question. For the purpose of marketing authorization, data from at least three lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided.
Case D: Where a known human pathogen, such as those indicated by footnote 1 in Table 3, is identified, the product may be acceptable only under exceptional circumstances. In this instance, it is recommended that the identified virus be used for virus removal and inactivation evaluation studies and specific methods with high specificity and sensitivity for the detection of the virus in question be employed. If it is not possible to use the identified virus, “relevant” and/or specific “model” viruses (described later) should be used. The process should be shown to achieve the removal and inactivation of the selected viruses during the purification and inactivation processes. Time-dependent inactivation data for the critical inactivation step(s) should be obtained as part of process evaluation. Purified bulk should be tested using suitable methods having high specificity and sensitivity for the detection of the virus in question. For the purpose of marketing authorization, data from at least three lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided.
Case E: When a virus that cannot be classified by currently available methodologies is detected in the cells or unprocessed bulk, the product is usually considered unacceptable since the virus may prove to be pathogenic. In the very rare case where there are convincing and well justified reasons for drug production using such a cell line, this should be discussed with the regulatory authorities before proceeding further.